 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Brett Stevens and Andrew Kent.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.355 |
|
|
|
-
Amaya ML, Abbott D, McMahon CM, Schwartz MS, Gutman JA, Kent A, Angelos MG, Sohalski C, Belachew A, Dell-Martin J, Anttila K, Stevens BM, D'Alessandro A, Showers WM, Gillen AE, Jordan CT, Pollyea DA. A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia. Blood Adv. 2026 Jul 24.
Score: 0.062
-
Patel SB, Moskop DR, Moreira S, Gipson S, Anderson CC, Crook A, McCabe M, Stephenson D, Terry HE, Kent A, Young TN, Krug AE, Thomas CI, Price C, Ransom M, Miller R, Vujovic A, Minhajuddin M, Althoff MJ, Consortium TC, Saviola AJ, Stevens BM, Welner RS, Andrianova EL, Gudkov AV, Darehshouri A, Reisz JA, Nemkov T, D'Alessandro A, Gillen AE, Pollyea DA, Jordan CT, Pietras EM. The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells. Blood Cancer Discov. 2026 Jul 21.
Score: 0.062
-
Patel SB, Moskop D, Moriera S, Gipson S, Anderson CC, Crook A, McCabe M, Stephenson D, Terry HE, Kent A, Young T, Krug A, Price C, Ransom M, Miller R, Vujovic A, Minhajuddin M, Althoff MJ, Saviola AJ, Stevens BM, Welner RS, Andrianova EL, Gudkov AV, Nemkov T, D Alessandro A, Gillen AE, Pollyea DA, Jordan CT, Pietras EM. The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells. bioRxiv. 2025 Dec 22.
Score: 0.060
-
O'Brien C, Nursimulu N, Tyagi A, Culp-Hill R, Arruda A, Murphy T, Minden MD, Kent A, Stevens B, Pollyea DA, Hope K, Kumar S, Reisz JA, D'Alessandro A, Jones CL. Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia. Blood. 2025 Nov 20; 146(21):2589-2596.
Score: 0.060
-
Pollyea DA, Stevens BM, Abbott D, Amaya M, Gutman JA, Kent A, McMahon C, Schwartz M, Smith C, Dell-Martin J, Sohalski C, Ellis A, Haag M, Schowinsky J, Pan Z, Patel SB, Ransom M, Gillen A, Jordan CT, Pietras EM. Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial. EClinicalMedicine. 2025 Nov; 89:103546.
Score: 0.059
-
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625.
Score: 0.051
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|